BCIQ Profiles

Company Profile Report

PART 1

ODAC consequences

PART 2

ODAC Day 3

PART 2

ODAC Day 2

PART 4

ODAC Day 1

0427 ODAC meeting
BioCentury & Getty Images

Regulation

Swayed by lack of alternatives, ODAC votes to retain Tecentriq accelerated approval for triple-negative breast cancer

Given lack of confirmatory data, the outcome could lower confidence in accelerated approval pathway

Given the drug’s lack of confirmatory data in the indication, the outcome could lower confidence in the accelerated approval pathway.

Apr 28, 2021 | 1:55 AM GMT

Read the full 601 word article

How to gain access

Continue reading with a
two-week free trial.